Treatment of malignant pleural effusions: the case for localized immunotherapy

Malignant pleural effusions (MPE) are a common terminal pathway for many cancers, with an estimated United States incidence of more than 150,000 cases per year. MPE is an aggressive disease with a uniformly fatal prognosis and a life expectancy of only 3 to 12 months. The development of an effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Donnenberg, Albert D., Luketich, James D., Dhupar, Rajeev, Donnenberg, Vera S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472034/
https://www.ncbi.nlm.nih.gov/pubmed/30999958
http://dx.doi.org/10.1186/s40425-019-0590-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472034/
https://www.ncbi.nlm.nih.gov/pubmed/30999958
http://dx.doi.org/10.1186/s40425-019-0590-4

Ejemplares similares